Compare FedEx Corporation (FDX) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FedEx Corporation vs Vertex Pharmaceuticals Incorporated — how do they compare? FedEx Corporation trades at $292 (market cap $68.41B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Vertex Pharmaceuticals Incorporated is the larger of the two by market cap, and FedEx Corporation pays a 1.69% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold FedEx Corporation for 87 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| FDX | VRTX | |
|---|---|---|
Market Cap | $68.41B | $128.16B |
Volume | 1,232,551 | 806,603 |
Sector | Industrials | Health |
52-Week High | $339.35 | $557.96 |
52-Week Low | $180.87 | $407.37 |
Typical Hold Time | 87 Days | 120 Days |
Enterprise Value | $98.04B | $122.29B |
Dividend Yield | 1.69% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FedEx (FDX) trades at $291.73, up 0.93% today, with a bearish technical signal from moving averages and oscillators. The company shows solid fundamentals with a P/E of 15.58 and net income margin of 4.68%, though revenue has been flat near $88B. Recent news includes a $300M electric truck order and shareholder approval of executive pay, while earnings have beaten estimates in recent quarters.
The outlook is mixed: analyst consensus is bullish with a $307.55 price target, but rising fuel costs and net cash outflows pose risks. Investment appeal lies in cost-cutting efforts and industry recovery, balanced against macroeconomic pressures and competitive threats in logistics.
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About FedEx Corporation
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2020 (ended May 2020), FedEx derived 51% of revenue from its express division, 33% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder comes from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016. TNT was previously the fourth-largest global parcel delivery provider.
Read more on FDX →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
